

Appraisal of Target Definition for Recurrent Cancers of the Supralottic Larynx

Murat Beyzadeoglu*, Selcuk Demiral, Ferrat Dincoglan and Omer Sager

Department of Radiation Oncology, University of Health Sciences, Gulhane Medical Faculty, Turkey

*Corresponding author: Murat Beyzadeoglu, Department of Radiation Oncology, University of Health Sciences, Gulhane Medical Faculty, Ankara, Turkey

ARTICLE INFO

Received: June 02, 2023

Published: June 08, 2023

Citation: Murat Beyzadeoglu, Selcuk Demiral, Ferrat Dincoglan and Omer Sager. Appraisal of Target Definition for Recurrent Cancers of the Supralottic Larynx. Biomed J Sci & Tech Res 50(5)-2023. BJSTR. MS.ID.008026.

ABSTRACT

Objective: Laryngeal cancers are among the most common of head and neck tumours which may cause considerable morbidity and mortality worldwide [1-7]. Nevertheless, successful results may be achieved by a multidisciplinary therapeutic approach. Surgery, chemotherapy, and radiation therapy (RT) may be utilized for laryngeal cancer management with respect to disease extent. Herein, we assessed target definition for recurrent cancers of the supraglottic larynx to explore the utility of multimodality imaging.

Materials and Methods: Objective of this study has been to assess target definition for recurrent supraglottic laryngeal cancer irradiation based on CT only or fused CT-MRI. We performed a comparative analysis evaluation of target definition by CT simulation images only or by incorporation of MRI. Besides assessment of integrated multimodality imaging for target definition, we also evaluated normal tissue delineation, interobserver and interobservers variations.

Results: Ground truth target volume has been utilized as the reference for comparative assessment, and our results have demonstrated that utilization of fused CT-MRI based target definition was identical with ground truth target definition in the selected group of patients with recurrent supraglottic laryngeal cancer.

Conclusion: Incorporation of MRI in RT target definition may be suggested for patients with recurrent supraglottic laryngeal cancers despite the need for further supporting evidence.

Keywords: Supraglottic Laryngeal Cancer; Radiation Therapy (RT); Magnetic Resonance Imaging (MRI)

Abbreviations: RT: Radiation Therapy; MRI: Magnetic Resonance Imaging; IGRT: Image Guided RT; IMRT: Intensity Modulated RT; ART: Adaptive RT; CT: Computed Tomography; AAPM: American Association of Physicists in Medicine; ICRU: International Commission on Radiation Units and Measurements

Introduction

Laryngeal cancers are among the most common of head and neck tumours which may cause considerable morbidity and mortality worldwide [1-7]. Nevertheless, successful results may be achieved by a multidisciplinary therapeutic approach. Surgery, chemotherapy, and radiation therapy (RT) may be utilized for laryngeal cancer management with respect to disease extent. Surgery may offer favourable outcomes; however, adverse effects of surgical interventions should be considered. RT may be used as the single management modality or as part of multidisciplinary management

for laryngeal cancers. It has also been proposed that laryngeal preservation strategies could be followed according to patient, tumor, and treatment characteristics. RT may also have a role as salvage treatment for recurrent disease. Advances in technology may obviously result in improved therapeutic outcomes for cancer in the millennium era.

Considering the critical location of laryngeal cancers in close vicinity of vital neurovascular structures, it is a priority to individualize patient management with multidisciplinary collaboration. Both the tumor and administered treatments may cause quality of life

impairment in affected patients, and adverse effects of management should be considered at the outset. Quality of life issues and normal tissue sparing must be considered as critical aspects of contemporary radiotherapeutic strategies. Integration of modernized treatment approaches and technologies such as molecular imaging methods, automatic segmentation techniques, Image Guided RT (IGRT), Intensity Modulated RT (IMRT), stereotactic RT, and adaptive RT (ART) may clearly result in improved radiotherapeutic outcomes [8-49]. However, improvements in target definition must be considered as an indispensable component of sophisticated RT protocols. In the meantime, widely adopted practice includes use of Computed Tomography (CT) simulation for acquisition of radiation treatment planning images, nevertheless, incorporation of other imaging modalities such as Magnetic Resonance Imaging (MRI) may admittedly add to the precision of target definition as suggested by other studies [50-96]. Herein, we assessed target definition for recurrent cancers of the supraglottic larynx to explore the utility of multimodality imaging.

Materials and Methods

We have been treating a huge patient population from several places from Turkey and abroad at Department of Radiation Oncology at Gulhane Medical Faculty, University of Health Sciences as a tertiary cancer center. In this context, variety of benign and malignant tumours are irradiated at our center for decades. Objective of this study has been to assess target definition for recurrent supraglottic laryngeal cancer irradiation based on CT only or fused CT-MRI. We performed a comparative analysis evaluation of target definition by CT simulation images only or by incorporation of MRI. Besides assessment of integrated multimodality imaging for target definition, we also evaluated normal tissue delineation, interobserver and interobservers variations. Ground truth target volume was used for comparative analysis, and it has been defined by board certified radiation oncologists following meticulous assessment of all imaging and relevant data with thorough colleague peer review and consensus. Decision making process for optimal patient management has involved multidisciplinary input from experts on surgical oncology, radiation oncology, and medical oncology. Individualized patient assessment included consideration of patient, disease, and treatment related factors. Patient age, previous treatments, symptomatology, lesion size, performance status, lesion localization and association with normal tissues, expected results of proposed treatment alternatives, patient preferences and logistical issues were also considered. Linear Accelerator (LINAC) with the capability of sophisticated IGRT techniques was used for irradiation. After rigid patient immobilization, planning CT images have been acquired at CT simulator for RT planning. Afterwards, acquired RT planning images were sent to the contouring workstation by the network. Target volumes and critical structures were defined on these images and structure sets were generated. Either CT simulation images only or fused CT-MR images were utilized for evaluation and comparative analysis of data.

Results

We have designed this original research article to evaluate the use of multimodality imaging with incorporation of MRI for RT target definition in a selected group of patients with recurrent supraglottic laryngeal cancer. Treatment of patients has been performed at our Radiation Oncology Department of Gulhane Medical Faculty at University of Health Sciences, Ankara. Before irradiation, patients have been assessed individually by a multidisciplinary team of experts from surgical oncology, medical oncology, and radiation oncology. Briefly, we carried out a comparative analysis based on either CT only imaging or by fused CT-MRI to assess the utility of this contemporary approach. Optimal RT planning process included consideration of lesion sizes, localization, and association with surrounding normal tissues. Radiation physicists have been included in RT planning procedure with consideration of reports by American Association of Physicists in Medicine (AAPM) and International Commission on Radiation Units and Measurements (ICRU). Accurate RT planning procedure included consideration of electron density, tissue heterogeneity, CT number and HU values in CT images. Main goal of RT planning was to accomplish optimal encompassing of target volumes with minimal exposure of surrounding normal tissues. Ground truth target volume has been utilized as the reference for comparative assessment, and our results have demonstrated that utilization of fused CT-MRI based target definition was identical with ground truth target definition in the selected group of patients with recurrent supraglottic laryngeal cancer.

Discussion

Laryngeal cancers account for a significant proportion among head and neck tumours and may cause considerable morbidity and mortality worldwide [1-7]. However, optimal therapeutic outcomes can be achieved by a multidisciplinary and collaborative treatment strategy. Surgery, chemotherapy, and RT can be used for laryngeal cancer management with regards to disease extent and other characteristics. Surgery can offer favourable treatment results in a considerable proportion of affected patients, nevertheless, untoward toxicity of surgical interventions must always be considered. RT can serve as the single treatment modality in certain circumstances and may also be utilized as part of multidisciplinary treatment of laryngeal cancers. Also, it has also proposed that laryngeal preservation strategies might be followed with respect to patient, tumor, and treatment characteristics. RT can also play a role as salvage treatment for recurrent cancer. Unprecedented improvements in technology can apparently lead to better treatment results for cancer in the millennium era. Considering the critical localization of laryngeal cancers in close neighbourhood of vital neurovascular structures, it should be considered as a priority to individualize patient management with multidisciplinary collaboration. Both tumour and utilized treatments can lead to quality-of-life deterioration in affected patients, and adverse effects of management should be considered at

the outset. Quality of life considerations and critical organ protection should be considered as pertinent aspects of sophisticated RT approaches. Incorporation of contemporary therapeutic strategies and technologies such as molecular imaging methods, automatic segmentation techniques, IGRT, IMRT, stereotactic RT, and ART can lead to better RT results [8-49]. Nevertheless, improvements in target definition must be considered as an indispensable component of sophisticated RT protocols. Nowadays, more common practice includes use of CT simulation for acquisition of RT planning images, however, integration of other imaging modalities such as MRI can possibly add to the accuracy of target definition as suggested by other studies [50-96]. To conclude, incorporation of MRI in RT target definition may be suggested for patients with recurrent supraglottic laryngeal cancers despite the need for further supporting evidence.

Conflict of Interest

None.

Acknowledgement

None.

References

1. Myers EN, Alvi A (1996) Management of carcinoma of the supraglottic larynx: evolution, current concepts, and future trends. *Laryngoscope* 106(5 Pt 1): 559-567.
2. Wendt CD, Peters LJ, Ang KK, Morrison WH, Maor MH, et al. (1989) Hyperfractionated radiotherapy in the treatment of squamous cell carcinomas of the supraglottic larynx. *Int J Radiat Oncol Biol Phys* 17(5): 1057-1062.
3. Issa PY (1988) Cancer of the supraglottic larynx treated by radiotherapy exclusively. *Int J Radiat Oncol Biol Phys* 15(4): 843-850.
4. Patel KB, Nichols AC, Fung K, Yoo J, MacNeil SD, et al. (2018) Treatment of early stage Supraglottic squamous cell carcinoma: meta-analysis comparing primary surgery versus primary radiotherapy. *J Otolaryngol Head Neck Surg* 47(1): 0-19.
5. Vermund H, Boysen M, Evensen JF, Jacobsen AB, Natvig K, et al. (1999) Survival of patients with squamous cell carcinoma of the supraglottic larynx--thirty-five-year experience with radiotherapy. *Acta Oncol* 38(7): 961-968.
6. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, et al. (2013) Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. *J Clin Oncol* 31(7): 845-852.
7. Mendenhall WM, Parsons JT, Mancuso AA, Stringer SP, Cassisi NJ, et al. (1996) Radiotherapy for squamous cell carcinoma of the supraglottic larynx: an alternative to surgery. *Head Neck* 18(1): 24-35.
8. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2022) Potential Utility of Radiopharmaceuticals in the Battle Against SARSCov- 2 and COVID-19 Pandemic. *Curr Radiopharm* 15(2): 93-95.
9. Oktay EA, Zerener T, Dirican B, Yıldız S, Sager O, et al. (2022) Dosimetric evaluation of the effect of dental restorative materials in head and neck radiotherapy. *Indian J Cancer* 59(3): 402-407.
10. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2022) Concise review of radiosurgery for contemporary management of pilocytic astrocytomas in children and adults. *World J Exp Med* 12(3): 36-43.
11. Gamsiz H, Sager O, Uysal B, Dincoglan F, Demiral S, et al. (2022) Active breathing control guided stereotactic body ablative radiotherapy for management of liver metastases from colorectal cancer. *Acta Gastroenterol Belg* 85(3): 469-475.
12. Sager O, Dincoglan F, Demiral S, Gamsiz H, Uysal B, et al. (2022) Optimal timing of thoracic irradiation for limited stage small cell lung cancer: Current evidence and future prospects. *World J Clin Oncol* 13(2): 116-124.
13. Demiral S, Sager O, Dincoglan F, Uysal B, Gamsiz H, et al. (2021) Evaluation of breathing-adapted radiation therapy for right-sided early stage breast cancer patients. *Indian J Cancer* 58(2): 195-200.
14. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2021) Omission of Radiation Therapy (RT) for Metaplastic Breast Cancer (MBC): A Review Article. *International Journal of Research Studies in Medical and Health Sciences* 6: 10-15.
15. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2021) Concise review of stereotactic irradiation for pediatric gliial neoplasms: Current concepts and future directions. *World J Methodol* 11(3): 61-74.
16. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2020) Adaptive radiation therapy of breast cancer by repeated imaging during irradiation. *World J Radiol* 12(5): 68-75.
17. Sager O, Beyzadeoglu M, Dincoglan F, Demiral S, Gamsiz H, et al. (2020) Multimodality management of cavernous sinus meningiomas with less extensive surgery followed by subsequent irradiation: Implications for an improved toxicity profile. *J Surg Surgical Res* 6(1): 056-061.
18. Beyzadeoglu M, Sager O, Dincoglan F, Demiral S, Uysal B, et al. (2020) Single Fraction Stereotactic Radiosurgery (SRS) versus Fractionated Stereotactic Radiotherapy (FSRT) for Vestibular Schwannoma (VS). *J Surg Surgical Res* 6(1): 062-066.
19. Dincoglan F, Beyzadeoglu M, Sager O, Demiral S, Uysal B, et al. (2020) A Concise Review of Irradiation for Temporal Bone Chemodectomas (TBC). *Arch Otolaryngol Rhinol* 6(2): 016-020.
20. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2019) Utility of Molecular Imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-DGlucose Positron Emission Tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): A Radiation Oncology Perspective. *Curr Radiopharm* 12(1): 4-10.
21. Dincoglan F, Sager O, Demiral S, Gamsiz H, Uysal B, et al. (2019) Fractionated stereotactic radiosurgery for locally recurrent brain metastases after failed stereotactic radiosurgery. *Indian J Cancer* 56(2): 151-156.
22. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, et al. (2019) Breathing adapted radiation therapy for leukemia relapse in the breast: A case report. *World J Clin Oncol* 10(11): 369-374.
23. Dincoglan F, Sager O, Uysal B, Demiral S, Gamsiz H, et al. (2019) Evaluation of hypofractionated stereotactic radiotherapy (HFSRT) to the resection cavity after surgical resection of brain metastases: A single center experience. *Indian J Cancer* 56(3): 202-206.
24. Sager O, Dincoglan F, Uysal B, Demiral S, Gamsiz H, et al. (2018) Evaluation of adaptive radiotherapy (ART) by use of replanning the tumor bed boost with repeated computed tomography (CT) simulation after whole breast irradiation (WBI) for breast cancer patients having clinically evident seroma. *Jpn J Radiol* 36(6): 401-406.
25. Demiral S, Dincoglan F, Sager O, Uysal B, Gamsiz H, et al. (2018) Contemporary Management of Meningiomas with Radiosurgery. *Int J Radiol Imaging Technol* 80: 187-190.
26. Sager O, Dincoglan F, Uysal B, Demiral S, Gamsiz H, et al. (2017) Splenic Irradiation: A Concise Review of the Literature. *J App Hem Bl Tran* 1: 101.
27. Dincoglan F, Sager O, Demiral S, Uysal B, Gamsiz H, et al. (2017) Radiosurgery for recurrent glioblastoma: A review article. *Neurol Disord Therap* 1(4): 1-5.

28. Demiral S, Dincoglan F, Sager O, Gamsiz H, Uysal B, et al. (2016) Hypofractionated stereotactic radiotherapy (HFSRT) for who grade I anterior clinoid meningiomas (ACM). *Jpn J Radiol* 34(11): 730-737.
29. Dincoglan F, Beyzadeoglu M, Sager O, Demiral S, Gamsiz H, et al. (2015) Management of patients with recurrent glioblastoma using hypofractionated stereotactic radiotherapy. *Tumori* 101(2): 179-184.
30. Gamsiz H, Beyzadeoglu M, Sager O, Demiral S, Dincoglan F, et al. (2015) Evaluation of stereotactic body radiation therapy in the management of adrenal metastases from non-small cell lung cancer. *Tumori* 101(1): 98-103.
31. Sager O, Beyzadeoglu M, Dincoglan F, Demiral S, Uysal B, et al. (2015) Adaptive splenic radiotherapy for symptomatic splenomegaly management in myeloproliferative disorders. *Tumori* 101(1): 84-90.
32. Sager O, Dincoglan F, Beyzadeoglu M (2015) Stereotactic radiosurgery of glomus jugulare tumors: Current concepts, recent advances and future perspectives. *CNS Oncol* 4(2): 105-114.
33. Sager O, Beyzadeoglu M, Dincoglan F, Uysal B, Gamsiz H, et al. (2014) Evaluation of linear accelerator (LINAC)-based stereotactic radiosurgery (SRS) for cerebral cavernous malformations: A 15-year single-center experience. *Ann Saudi Med* 34(1): 54-58.
34. Demiral S, Beyzadeoglu M, Sager O, Dincoglan F, Gamsiz H, et al. (2014) Evaluation of Linear Accelerator (Linac)-Based Stereotactic Radiosurgery (Srs) for the Treatment of Craniopharyngiomas. *UHOD-Uluslararası Hematoloji-Onkoloji Dergisi* 24(2): 123-129.
35. Sager O, Beyzadeoglu M, Dincoglan F, Gamsiz H, Demiral S, et al. (2014) Evaluation of linear accelerator-based stereotactic radiosurgery in the management of glomus jugulare tumors. *Tumori* 100(2): 184-188.
36. Ozsavaş EE, Telatar Z, Dirican B, Sager O, Beyzadeoglu M (2014) Automatic segmentation of anatomical structures from CT scans of thorax for RTP. *Comput Math Methods Med* 2014: 472890.
37. Demiral S, Beyzadeoglu M, Sager O, Dincoglan F, Gamsiz H, et al. (2014) Evaluation of linear accelerator (linac)-based stereotactic radiosurgery (srs) for the treatment of craniopharyngiomas. *UHOD - Uluslararası Hematoloji-Onkoloji Dergisi* 24: 123-129.
38. Gamsiz H, Beyzadeoglu M, Sager O, Dincoglan F, Demiral S, et al. (2014) Management of pulmonary oligometastases by stereotactic body radiotherapy. *Tumori* 100(2): 179-183.
39. Dincoglan F, Sager O, Gamsiz H, Uysal B, Demiral S, et al. (2014) Management of patients with ≥ 4 brain metastases using stereotactic radiosurgery boost after whole brain irradiation. *Tumori* 100(3): 302-306.
40. Sager O, Beyzadeoglu M, Dincoglan F, Demiral S, Uysal B, et al. (2013) Management of vestibular schwannomas with linear accelerator-based stereotactic radiosurgery: a single center experience. *Tumori* 99(5): 617-622.
41. Dincoglan F, Beyzadeoglu M, Sager O, Uysal B, Demiral S, et al. (2013) Evaluation of linear accelerator-based stereotactic radiosurgery in the management of meningiomas: A single center experience. *J BUON* 18(3): 717-722.
42. Dincoglan F, Beyzadeoglu M, Sager O, Oysul K, Kahya YE, et al. (2013) Dosimetric evaluation of critical organs at risk in mastectomized left-sided breast cancer radiotherapy using breath-hold technique. *Tumori* 99(1): 76-82.
43. Demiral S, Beyzadeoglu M, Uysal B, Oysul K, Kahya YE, et al. (2013) Evaluation of stereotactic body radiotherapy (SBRT) boost in the management of endometrial cancer. *Neoplasma* 60(3): 322-327.
44. Sager O, Beyzadeoglu M, Dincoglan F, Oysul K, Kahya YE, et al. (2012) Evaluation of active breathing control-moderate deep inspiration breath-hold in definitive non-small cell lung cancer radiotherapy. *Neoplasma* 59(3): 333-340.
45. Sağer Ö, Dincoglan F, Gamsiz H, Demiral S, Uysal B, et al. (2012) Evaluation of the impact of integrated [18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging on staging and radiotherapy treatment volume definition of nonsmall cell lung cancer. *Gulhane Med J* 54: 220-227.
46. Sager O, Beyzadeoglu M, Dincoglan F, Oysul K, Kahya YE, et al. (2012) The Role of Active Breathing Control-Moderate Deep Inspiration Breath-Hold (ABC-mDIBH) Usage in non-Mastectomized Left-sided Breast Cancer Radiotherapy: A Dosimetric Evaluation UHOD - Uluslararası Hematoloji-Onkoloji Dergisi 22: 147-155.
47. Dincoglan F, Sager O, Gamsiz H, Uysal B, Demiral S, et al. (2012) Stereotactic radiosurgery for intracranial tumors: A single center experience. *Gulhane Med J* 54: 190-198.
48. Dincoglan F, Beyzadeoglu M, Sager O, Oysul K, Sirin S, et al. (2012) Image-guided positioning in intracranial non-invasive stereotactic radiosurgery for the treatment of brain metastasis. *Tumori* 98(5): 630-635.
49. Sirin S, Oysul K, Surenkok S, Sager O, Dincoglan F, et al. (2011) Linear accelerator-based stereotactic radiosurgery in recurrent glioblastoma: A single center experience. *Vojnosanit Pregl* 68(11): 961-966.
50. Beyzadeoglu M, Dincoglan F, Demiral S, Sager O (2023) An Original Article Revisiting the Utility of Multimodality Imaging For Refined Target Volume Determination Of Recurrent Kidney Carcinoma. *Canc Therapy & Oncol Int J* 23(5): 556122.
51. Beyzadeoglu M, Demiral S, Dincoglan F, Sager O (2022) Assessment of Target Definition for Extramedullary Soft Tissue Plasmacytoma: Use of Multimodality Imaging for Improved Targeting Accuracy. *Canc Therapy & Oncol Int J* 22(4): 556095.
52. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2022) Target Volume Determination for Recurrent Uterine Carcinosarcoma: An Original Research Article Revisiting the Utility of Multimodality Imaging. *Canc Therapy & Oncol Int J* 22(3): 556090.
53. Demiral S, Sager O, Dincoglan F, Beyzadeoglu M (2022) Reappraisal of Computed Tomography (CT) And Magnetic Resonance Imaging (MRI) Based Target Definition for Radiotherapeutic Management of Recurrent Anal Squamous Cell Carcinoma (ASCC): An Original Article. *Canc Therapy & Oncol Int J* 22(2): 556085.
54. Demiral S, Dincoglan F, Sager O, Beyzadeoglu M (2022) An Original Article for Assessment of Multimodality Imaging Based Precise Radiation Therapy (Rt) in the Management of Recurrent Pancreatic Cancers. *Canc Therapy & Oncol Int J* 22(1): 556078.
55. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M (2022) Assessment of Target Volume Definition for Precise Radiotherapeutic Management of Locally Recurrent Biliary Tract Cancers: An Original Research Article. *Biomed J Sci & Tech Res* 46(1): 37054-37059.
56. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M (2022) Radiation Therapy (RT) Target Volume Determination for Locally Advanced Pyriform Sinus Carcinoma: An Original Research Article Revisiting the Role of Multimodality Imaging. *Biomed J Sci & Tech Res* 45(1): 36155-36160.
57. Demiral S, Sager O, Dincoglan F, Beyzadeoglu M (2022) Improved Target Volume Definition for Radiotherapeutic Management of Parotid Gland Cancers by use of Multimodality Imaging: An Original Article. *Canc Therapy & Oncol Int J* 21(3): 556062.
58. Beyzadeoglu M, Sager O, Demiral S, Dincoglan F (2022) Reappraisal of multimodality imaging for improved Radiation Therapy (RT) target volume determination of recurrent Oral Squamous Cell Carcinoma (OSCC): An original article. *J Surg Surgical Res* 8: 004-008.
59. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2022) Multimodality imaging based treatment volume definition for recurrent Rhabdomyosarcomas of the head and neck region: An original article. *J Surg Surgical Res* 8(2): 013-018.

60. Dincoglan F, Demiral S, Sager O, Beyzadeoglu M (2022) Appraisal of Target Definition for Management of Paraspinal Ewing Tumors with Modern Radiation Therapy (RT): An Original Article. *Biomed J Sci & Tech Res* 44(4): 35691-35696.
61. Beyzadeoglu M, Sager O, Demiral S, Dincoglan F (2022) Assessment of Target Volume Definition for Contemporary Radiotherapeutic Management of Retroperitoneal Sarcoma: An Original Article. *Biomed J Sci & Tech Res* 44(5): 35883-35887.
62. Demiral S, Dincoglan F, Sager O, Beyzadeoglu M (2021) Assessment of Multimodality Imaging for Target Definition of Intracranial Chondrosarcomas. *Canc Therapy Oncol Int J* 18: 001-005.
63. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2021) Impact of Multimodality Imaging to Improve Radiation Therapy (RT) Target Volume Definition for Malignant Peripheral Nerve Sheath Tumor (MPNST). *Biomed J Sci Tech Res* 34: 26734-26738.
64. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M (2021) Multimodality Imaging Based Treatment Volume Definition for Reirradiation of Recurrent Small Cell Lung Cancer (SCLC). *Arch Can Res* 9: 1-5.
65. Demiral S, Sager O, Dincoglan F, Beyzadeoglu M (2021) Radiation Therapy (RT) Target Volume Definition for Peripheral Primitive Neuroectodermal Tumor (PPNET) by Use of Multimodality Imaging: An Original Article. *Biomed J Sci & Tech Res* 34: 26970-26974.
66. Dincoglan F, Demiral S, Sager O, Beyzadeoglu M (2021) Evaluation of Target Definition for Management of Myxoid Liposarcoma (MLS) with Neoadjuvant Radiation Therapy (RT). *Biomed J Sci Tech Res* 33: 26171-26174.
67. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2021) Radiation Therapy (RT) target determination for irradiation of bone metastases with soft tissue component: Impact of multimodality imaging. *J Surg Surgical Res* 7: 042-046.
68. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2021) Evaluation of Changes in Tumor Volume Following Upfront Chemotherapy for Locally Advanced Non Small Cell Lung Cancer (NSCLC). *Glob J Cancer Ther* 7: 031-034.
69. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M (2021) Assessment of posterior fossa target definition by multimodality imaging for patients with medulloblastoma. *J Surg Surgical Res* 7: 037-041.
70. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2021) Assessment of the role of multimodality imaging for treatment volume definition of intracranial ependymal tumors: An original article. *Glob J Cancer Ther* 7: 043-045.
71. Beyzadeoglu M, Dincoglan F, Demiral S, Sager O (2020) Target Volume Determination for Precise Radiation Therapy (RT) of Central Neurocytoma: An Original Article. *International Journal of Research Studies in Medical and Health Sciences* 5: 29-34.
72. Dincoglan F, Demiral S, Sager O, Beyzadeoglu M (2020) Utility of Multimodality Imaging Based Target Volume Definition for Radiosurgery of Trigeminal Neuralgia: An Original Article. *Biomed J Sci & Tech Res* 26: 19728-19732.
73. Demiral S, Beyzadeoglu M, Dincoglan F, Sager O (2020) Assessment of Target Volume Definition for Radiosurgery of Atypical Meningiomas with Multimodality Imaging. *Journal of Hematology and Oncology Research* 3: 14-21.
74. Dincoglan F, Beyzadeoglu M, Demiral S, Sager O (2020) Assessment of Treatment Volume Definition for Irradiation of Spinal Ependymomas: an Original Article. *ARC Journal of Cancer Science* 6(1): 1-6.
75. Sager O, Demiral S, Dincoglan F, Beyzadeoglu M (2020) Target Volume Definition for Stereotactic Radiosurgery (SRS) Of Cerebral Cavernous Malformations (CCMs). *Canc Therapy & Oncol Int J* 15: 555917.
76. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Treatment Volume Determination for Irradiation of Recurrent Nasopharyngeal Carcinoma with Multimodality Imaging: An Original Article. *ARC Journal of Cancer Science* 6(2): 18-23.
77. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Assessment of Target Volume Definition for Irradiation of Hemangiopericytomas: An Original Article. *Canc Therapy & Oncol Int J* 17(2): 555959.
78. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Evaluation of Treatment Volume Determination for Irradiation of chordoma: an Original Article. *International Journal of Research Studies in Medical and Health Sciences* 5(10): 3-8
79. Demiral S, Dincoglan F, Sager O, Beyzadeoglu M (2020) Multimodality Imaging Based Target Definition of Cervical Lymph Nodes in Precise Limited Field Radiation Therapy (Lfrt) for Nodular Lymphocyte Predominant Hodgkin Lymphoma (Nlphl). *ARC Journal of Cancer Science* 6: 06-11.
80. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Radiosurgery Treatment Volume Determination for Brain Lymphomas with and without Incorporation of Multimodality Imaging. *Journal of Medical Pharmaceutical and Allied Sciences* 9: 2398-2404.
81. Beyzadeoglu M, Dincoglan F, Sager O, Demiral S (2020) Determination of Radiosurgery Treatment Volume for Intracranial Germ Cell Tumors (GCTS). *Asian Journal of Pharmacy, Nursing and Medical Sciences* 8: 18-23.
82. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2020) Target Definition of orbital Embryonal Rhabdomyosarcoma (Rms) by Multimodality Imaging: An Original Article. *ARC Journal of Cancer Science* 6(2): 12-17.
83. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2020) Evaluation of Target Volume Determination for Irradiation of Pilocytic Astrocytomas: An Original Article. *ARC Journal of Cancer Science* 6: 1-5.
84. Demiral S, Beyzadeoglu M, Dincoglan F, Sager O (2020) Evaluation of Radiosurgery Target Volume Definition for Tectal Gliomas with Incorporation of Magnetic Resonance Imaging (MRI): An Original Article. *Biomedical Journal of Scientific & Technical Research (BJSTR)* 27: 20543-20547.
85. Beyzadeoglu M, Sager O, Dincoglan F, Demiral S (2019) Evaluation of Target Definition for Stereotactic Reirradiation of Recurrent Glioblastoma. *Arch Can Res* 7: 3.
86. Sager O, Dincoglan F, Demiral S, Gamsiz H, Uysal B, et al. (2019) Evaluation of the Impact of Magnetic Resonance Imaging (MRI) on Gross Tumor Volume (GTV) Definition for Radiation Treatment Planning (RTP) of Inoperable High Grade Gliomas (HGGs). *Concepts in Magnetic Resonance Part A* 2019, Article ID: 4282754.
87. Sager O, Dincoglan F, Demiral S, Gamsiz H, Uysal B, et al. (2019) Utility of Magnetic Resonance Imaging (Imaging) in Target Volume Definition for Radiosurgery of Acoustic Neuromas. *Int J Cancer Clin Res* 6: 119.
88. Demiral S, Sager O, Dincoglan F, Beyzadeoglu M (2019) Assessment of Computed Tomography (CT) And Magnetic Resonance Imaging (MRI) Based Radiosurgery Treatment Planning for Pituitary Adenomas. *Canc Therapy & Oncol Int J* 13: 555857.
89. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2019) Multimodality Imaging for Radiosurgical Management of Arteriovenous Malformations. *Asian Journal of Pharmacy, Nursing and Medical Sciences* 7: 7-12.
90. Sager O, Dincoglan F, Demiral S, Beyzadeoglu M (2019) Evaluation of Radiosurgery Target Volume Determination for Meningiomas Based on Computed Tomography (CT) And Magnetic Resonance Imaging (MRI). *Cancer Sci Res Open Access* 5: 1-4.
91. Demiral S, Sager O, Dincoglan F, Beyzadeoglu M (2019) Assessment of target definition based on Multimodality imaging for radiosurgical Management of glomus jugulare tumors (GJTs). *Canc Therapy & Oncol Int J* 15: 555909.
92. Dincoglan F, Sager O, Demiral S, Beyzadeoglu M (2019) Incorporation of Multimodality Imaging in Radiosurgery Planning for Craniopharyngiomas: An Original Article. *SAJ Cancer Sci* 6: 103.

93. Demiral S, Sager O, Dincoglan F, Uysal B, Gamsiz H, et al. (2018) Evaluation of Target Volume Determination for Single Session Stereotactic Radiosurgery (SRS) of Brain Metastases. *Canc Therapy & Oncol Int J* 12: 555848.
94. Jager EA, Kasperts N, Caldas-Magalhaes J, Philippens ME, Pameijer FA, et al. (2015) GTV delineation in supraglottic laryngeal carcinoma: interobserver agreement of CT versus CT-MR delineation. *Radiat Oncol* 10: 26.
95. Caldas-Magalhaes J, Kooij N, Ligtenberg H, Jager EA, Schakel T, et al. (2015) The accuracy of target delineation in laryngeal and hypopharyngeal cancer. *Acta Oncol* 54(8): 1181-1187.
96. Jager EA, Ligtenberg H, Caldas-Magalhaes J, Schakel T, Philippens ME, et al. (2016) Validated guidelines for tumor delineation on magnetic resonance imaging for laryngeal and hypopharyngeal cancer. *Acta Oncol* 55(11): 1305-1312.

ISSN: 2574-1241

DOI: 10.26717/BJSTR.2023.50.008026

Murat Beyzadeoglu. Biomed J Sci & Tech Res



This work is licensed under Creative
Commons Attribution 4.0 License

Submission Link: <https://biomedres.us/submit-manuscript.php>



Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

<https://biomedres.us/>